Women with a past history of migraine have a 15% higher risk of developing hypertension than those with no history of migraine, according to study findings published in Cephalalgia.
Women who have migraines have a higher risk of developing hypertension, according to study findings published in Cephalalgia.1
Links between migraine and vascular issues, such as migraine with aura and increased stroke risk, have been assessed for decades. However, the association between migraine and hypertension has been inconclusive.
“Better understanding whether migraineurs are at increased risk for developing hypertension is important, as it may inform clinical management as well as elucidate possible strategies to prevent hypertension and the potential influence of this association in the development of coronary disease in patients with migraine,” according to the authors of the study.
The researchers conducted a prospective study of 29,040 women with no hypertension at baseline. Women were categorized as having active migraine with aura, active migraine without aura, a past history of migraine, or no history of migraine. Incident hypertension was defined as a new physician diagnosis or newly self-reported systolic or diastolic blood pressure of 140 mmHg and higher or 90 mmHg and higher, respectively.
Among the participants, 23,819 (82%) reported no history of migraine and 5221 (18%) reported any history of migraine. Of the women who reported history of migraine, 1516 (29%) reported migraine with aura, 2294 (43.9%) reported migraine without aura, and 1411 (27%) reported a past history of migraine.
During a mean follow-up of 12.2 years, there were a total of 15,176 incident hypertension events, 2868 of which occurred among those with any history of migraine. Women with a past history of migraine had a 15% higher risk of developing hypertension than those with no history of migraine.
Women who experienced migraine without aura had the highest risk of developing hypertension, with a 21% increased risk when compared to women with no history of migraine, while women who experienced migraine with aura had a 9% increased risk. Women who had a migraine frequency of at least weekly had a 30% increased risk when compared to those with fewer than 6 migraines per year.
According to the researchers, the link between migraine and incident hypertension could have 2 potential causes: shared factors that lead to both migraine and hypertension, but at different time points, may exist; and aspects or consequences of migraine pathophysiology may increase the propensity for developing hypertension.
“Despite the small to moderate increase in the relative risk of developing hypertension, our results have clinical implications given the high prevalence of migraine at the population level,” concluded the authors. “Moreover, as patients with migraine are at risk of developing cardiovascular disease, detection of any additional vascular risk factor will assist in implementing a more individualized therapeutic regimen.”
Of the 38 million people in the United States who experience migraines, 75% are women, a fact that may be attributable to the way fluctuations in estrogen levels affect cells in the brain.
Reference
1. Rist P, Winter A, Buring J, et al. Migraine and the risk of incident hypertension among women. [Published online February 1, 2018]. Cephalalgia. doi: 10.1177/0333102418756865.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More